Chemotherapy in Metastatic Nonanaplastic Thyroid Cancer: Experience at the Institut Gustave-Roussy

Abstract

Forty-nine patients with metastatic nonanaplastic thyroid carcinoma were treated over a 10-year period. Five successive chemotherapeutic protocols were used: a combination of doxorubicin, etoposide, 5-fluorouracil and cyclophosphamide; elliptinium acetate; doxorubicin; cisplatin; and the combination of doxorubicin and cisplatin. Results obtained with the different protocols were very disappointing, with only two objective responses (3%). Phase II trials with new chemotherapeutic agents are warranted in selected cases of nonanaplastic metastatic thyroid carcinoma.

Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine

“…Combination of doxorubicn with other drugs such as cisplatin (Shimaoka et al, 1985;Sridhar et al, 1985;Williams et al, 1986;Droz et al, 1990), or streptozocin (Kelson et al, 1982 did not increase the response rate.…”

“…Response rates were low with doxorubicin (Gottlieb and Hill 1975;Husain et al, 1978;Shimaoka et al, 1985;Hosidn and Harmer, 1987;Droz et al, 1990) and cisplatin (Hosin and Harmer, 1987;Droz et al, 1990), given either as single agents or in combination (Shimaoka et al, 1985;Sridhar et al, 1985;Williams et al, 1986;Droz et al, 1990). Furthermore, toxcities were siant.…”

2016 Russian clinical practice guidelines for differentiated thyroid cancer diagnosis and treatment

“…Таргетная терапия [1, [229][230][231][232][233][234][235][236][237] Рекомендация 47. Системная таргет-ная терапия препаратами, зарегистрирован-ными в РФ по данным медицинским показа-ниям (сорафениб и ленватиниб), показана при неэффективности РЙТ и доказанном про-грессировании опухоли в течение 3-12 мес согласно критериям RECIST 1.1 в случаях:…”

Defining a rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS): considerations and challenges towards developing an appropriate roadmap

“…The median progression-free survival was 18.3 versus 3.6 months in favour of lenvatinib as compared with placebo. Similarly, the rate of discontinuation of lenvatinib due to adverse effects was 14.2 % [23]. Although most responses with these agents have been reported to produce Bstable disease^, in practice their use is associated with substantial comorbidities leading to drug discontinuation.…”

“…Chemotherapy with standard agents (e.g. doxorubicin, cisplatin and taxanes) and thalidomide has not been popular because of unconvincing results with significant toxicity, whereas a newer thalidomide analogue lenalidomide needs to be investigated further [23][24][25][26][27][28]. To summarize, the major issues with these agents have been the requirement for more consistent results from multiple centres that would further validate the initially reported promising results.…”